UBS Reiterates a 'Buy' on St. Jude Medical (STJ); Positive After Analyst Meeting
Tweet
Share
E-mailGet Alerts STJ Hot Sheet
Price: $80.82 --0%
Rating Summary:
3 Buy, 21 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 8 | New: 11
Rating Summary:
3 Buy, 21 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 8 | New: 11
Join SI Premium – FREE
UBS reiterates a 'Buy' on St. Jude Medical (NYSE: STJ) price target raised from $42 to $48.
UBS analyst said, "We continue to see STJ is one of very few large cap companies that has been able to consistently develop new products without heavy reliance on M&A. While ICD dynamics will continue to be a key part of the story in 2012, STJ’s pipeline seems to position it well over the long-term."
"In our view, 4 factors are important for STJ over the next 12 months: Quadrapole share gains, ICD market growth, Durata integrity & Portico TAVI profile / uptake. While STJ may have lost denovo US ICD share in 4Q11, Quadrapole is probably capable of reversing the trend in 2012. On the ICD market, trajectory will be a headwind and we would not be surprised with continued softness in 2H12. On Durata, there still does not appear to be any evidence of a problematic defect."
For an analyst ratings summary and ratings history on St. Jude Medical click here. For more ratings news on St. Jude Medical click here.
Shares of St. Jude Medical closed at $42.51 yesterday.
UBS analyst said, "We continue to see STJ is one of very few large cap companies that has been able to consistently develop new products without heavy reliance on M&A. While ICD dynamics will continue to be a key part of the story in 2012, STJ’s pipeline seems to position it well over the long-term."
"In our view, 4 factors are important for STJ over the next 12 months: Quadrapole share gains, ICD market growth, Durata integrity & Portico TAVI profile / uptake. While STJ may have lost denovo US ICD share in 4Q11, Quadrapole is probably capable of reversing the trend in 2012. On the ICD market, trajectory will be a headwind and we would not be surprised with continued softness in 2H12. On Durata, there still does not appear to be any evidence of a problematic defect."
For an analyst ratings summary and ratings history on St. Jude Medical click here. For more ratings news on St. Jude Medical click here.
Shares of St. Jude Medical closed at $42.51 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UCB (UCB:BB) (UCBJY) PT Raised to EUR135 at UBS
- Morgan Stanley Double Downgrades AU Optronics (2409:TT) (AUO) to Underweight
- Chipotle Mexican Grill (CMG) PT Raised to $3,285 at Wells Fargo
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
UBSSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
